Literature DB >> 3501990

Thyroid disorders in the general population of Hisayama Japan, with special reference to prevalence and sex differences.

K Okamura1, T Nakashima, K Ueda, K Inoue, T Omae, M Fujishima.   

Abstract

Serum triiodothyronine (T3), thyroxine (T4), thyroid stimulating hormone (TSH) and thyroid autoantibodies (TAA) to either microsome or thyroglobulin were measured in 1251 samples from the general population, 546 males and 705 females, aged 40 or over in Hisayama, a Japanese rural town. TAA was positive in 7.7% of men and 15.0% of women, and the male/female ratio was 1:2. This ratio was markedly different from those in hospital patients with thyroid disorders where ratios such as 1:8 for chronic thyroiditis and 1:4 for Graves' disease were found. Among the study subjects, definite hyperthyroidism was found in 0.2%, borderline hyperthyroidism in 0.7%, overt hypothyroidism in 0.3%, latent hypothyroidism in 4.2%, and non-thyroid illness in 2.4%. Overt thyroid dysfunction was more evident in women, while latent thyroid dysfunction or non-thyroidal illness was equally prevalent in men and women. These results indicate that the incidence of immunologically or functionally latent thyroid disorders is rather higher than expected, in both women and men. Some unknown factor(s) might act as a trigger to manifest thyroid dysfunction, mainly in females.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3501990     DOI: 10.1093/ije/16.4.545

Source DB:  PubMed          Journal:  Int J Epidemiol        ISSN: 0300-5771            Impact factor:   7.196


  14 in total

Review 1.  The incidence and prevalence of thyroid autoimmunity.

Authors:  Donald S A McLeod; David S Cooper
Journal:  Endocrine       Date:  2012-05-29       Impact factor: 3.633

2.  Prevalence of subclinical hypothyroidism in a population living in the Milan metropolitan area.

Authors:  G Rivolta; R Cerutti; R Colombo; G Miano; P Dionisio; E Grossi
Journal:  J Endocrinol Invest       Date:  1999-10       Impact factor: 4.256

Review 3.  Thyroglobulin as a biomarker of iodine deficiency: a review.

Authors:  Zheng Feei Ma; Sheila A Skeaff
Journal:  Thyroid       Date:  2014-06-12       Impact factor: 6.568

4.  Importance of specific reference values for evaluation of the deteriorating thyroid function in patients with end-stage renal disease on hemodialysis.

Authors:  Toru Sanai; Ken Okamura; Tomoya Kishi; Motoaki Miyazono; Yuji Ikeda; Takanari Kitazono
Journal:  J Endocrinol Invest       Date:  2014-07-05       Impact factor: 4.256

5.  High prevalence of thyroid abnormalities in a Chilean psychiatric outpatient population.

Authors:  C Fardella; S Gloger; R Figueroa; R Santis; C Gajardo; C Salgado; S Barroilhet; A Foradori
Journal:  J Endocrinol Invest       Date:  2000-02       Impact factor: 4.256

6.  Descriptive epidemiology of thyroid cancer in the Swiss Canton of Vaud.

Authors:  F Levi; S Franceschi; V C Te; E Negri; C La Vecchia
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

7.  The prevalence of thyroid dysfunction in Jordan: a national population-based survey.

Authors:  Kamel M Ajlouni; Nahla Khawaja; Mohammed El-Khateeb; Anwar Batieha; Oraib Farahid
Journal:  BMC Endocr Disord       Date:  2022-10-20       Impact factor: 3.263

8.  Screening for thyroid disorders in a working population.

Authors:  L Schaaf; T Pohl; R Schmidt; I Vardali; J Teuber; B Schlote-Sauter; B Nowotny; H Schiebeler; A Zober; K H Usadel
Journal:  Clin Investig       Date:  1993-02

9.  Spectrum and Prevalence of Thyroid Disorders in Patients Admitted to the Anaesthesiology Outpatient Clinic for Surgery.

Authors:  Aykut Sarıtaş; Pelin Uzun Sarıtaş; Muhammed Murat Kurnaz; Abdullah Çelik
Journal:  Turk J Anaesthesiol Reanim       Date:  2015-03-03

10.  Masked hyperthyroidism in a haemodialysis patient successfully treated by potassium iodide.

Authors:  Toru Sanai; Ken Okamura; Kaori Sato; Syuichi Rikitake; Tomoya Kishi; Motoaki Miyazono; Yuji Ikeda
Journal:  Clin Kidney J       Date:  2012-01-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.